FDA Issues Approvable Letter for Bonefos (Clodronate) for Adjuvant Treatment of Breast Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Issues Approvable Letter for Bonefos (Clodronate) for Adjuvant Treatment of Breast Cancer

BERLIN, GERMANY -- January 7, 2005 -- Schering AG, Germany (FSE: SCH, NYSE: SHR) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for Bonefos® (clodronate), an oral non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients.

Berlex, Inc., Schering's U.S. affiliate, plans to request a meeting with the FDA to discuss the information that is needed to obtain approval, and will submit this information as quickly as possible.

"We look forward to the opportunity to meet with the FDA so we can advance the approval process," said Marc Rubin, MD, member of the Schering AG Board of Executive Directors responsible for Development and Oncology.

This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.

SOURCE: Schering AG

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities